Literature DB >> 19368662

Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry.

M Camilleri1, A Nadeau, W J Tremaine, J Lamsam, D Burton, S Odunsi, S Sweetser, R Singh.   

Abstract

Bile acid malabsorption (BAM) is reported in up to 50% of patients with functional diarrhoea and irritable bowel syndrome with diarrhoea (IBS-D). Serum 7alpha-hydroxy-4-cholesten-3-one (7alphaHCO or 7alphaC4), an indirect measurement of hepatic bile acid synthesis, has been validated as a measurement of BAM relative to the (75)SeHCAT retention test. Our aim was to develop a serum 7alphaC4 assay, normal values, and compare results from healthy controls, patients with ileal Crohn's disease or resection, and patients with IBS-D or IBS with constipation (IBS-C). Stored serum samples were used from adult men and women in the following groups: 111 normal healthy controls, 15 IBS-D, 15 IBS-C, 24 with distal ileal Crohn's disease and 20 with distal ileal resection for Crohn's disease. We adapted a published high pressure liquid chromatography, tandem mass spectrometry (HPLC-MS/MS) assay. The HPLC-MS/MS assay showed good linearity in concentration range 0-200 ng mL(-1), sensitivity (lowest limit of detection 0.04 ng mL(-1)), and high analytical recovery (average 99%, range 93-107%). The 5th to 95th percentile for 111 normal healthy controls was 6-60.7 ng mL(-1). There were significant overall group differences (anovaon ranks, P < 0.001), with significantly higher values for terminal ileal disease or resection. There were significant differences between health and IBS (anova, P = 0.043) with higher mean values in IBS-D relative to controls (rank sum test, P = 0.027). We have established a sensitive non-isotopic assay based on HPLC-MS/MS, determined normal 7alphaC4 values, and identified increased 7alphaC4 in IBS-D and in distal ileal resection and disease. This assay has potential as a non-invasive test for BAM in IBS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368662      PMCID: PMC2705747          DOI: 10.1111/j.1365-2982.2009.01288.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  33 in total

1.  The proximal colonic motor response to rectal mechanical and chemical stimulation.

Authors:  P A Bampton; P G Dinning; M L Kennedy; D Z Lubowski; I J Cook
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-03       Impact factor: 4.052

2.  Symptomatic overlap between irritable bowel syndrome and microscopic colitis.

Authors:  David Limsui; Darrell S Pardi; Michael Camilleri; Edward V Loftus; Patricia P Kammer; William J Tremaine; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2007-02       Impact factor: 5.325

3.  Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis.

Authors:  Cecilia Gälman; Bo Angelin; Mats Rudling
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

Review 4.  Colesevelam hydrochloride.

Authors:  Karen L Steinmetz
Journal:  Am J Health Syst Pharm       Date:  2002-05-15       Impact factor: 2.637

5.  Highly sensitive quantification of 7alpha-hydroxy-4-cholesten-3-one in human serum by LC-ESI-MS/MS.

Authors:  Akira Honda; Kouwa Yamashita; Mitsuteru Numazawa; Tadashi Ikegami; Mikio Doy; Yasushi Matsuzaki; Hiroshi Miyazaki
Journal:  J Lipid Res       Date:  2006-11-08       Impact factor: 5.922

6.  Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre.

Authors:  R Sadik; P-O Stotzer; M Simrén; H Abrahamsson
Journal:  Neurogastroenterol Motil       Date:  2007-11-05       Impact factor: 3.598

7.  Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome.

Authors:  Michael Camilleri; Sanna McKinzie; Irene Busciglio; Phillip A Low; Seth Sweetser; Duane Burton; Kari Baxter; Michael Ryks; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2008-05-05       Impact factor: 11.382

8.  Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome.

Authors:  M H Larsson; M Simrén; E A Thomas; J C Bornstein; E Lindström; H Sjövall
Journal:  Neurogastroenterol Motil       Date:  2007-10       Impact factor: 3.598

9.  Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics.

Authors:  Fernando Fernández-Bañares; Maria Esteve; Antonio Salas; Montserrat Alsina; Carme Farré; Clarisa González; Montse Buxeda; Montserrat Forné; Mercé Rosinach; Jorge C Espinós; Josep Maria Viver
Journal:  Am J Gastroenterol       Date:  2006-08-04       Impact factor: 10.864

10.  beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes.

Authors:  Jyoti Sinha; Frank Chen; Tamir Miloh; Robert C Burns; Zhisheng Yu; Benjamin L Shneider
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

View more
  57 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea.

Authors:  Banny S Wong; Michael Camilleri; Paula Carlson; Sanna McKinzie; Irene Busciglio; Olga Bondar; Roy B Dyer; Jesse Lamsam; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

3.  Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls.

Authors:  Archana S Rao; Michael Camilleri; Deborah J Eckert; Irene Busciglio; Duane D Burton; Michael Ryks; Banny S Wong; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

4.  Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.

Authors:  Banny S Wong; Michael Camilleri; Paula J Carlson; Suwebatu Odunsi-Shiyanbade; Sanna McKinzie; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Dis Sci       Date:  2012-01-21       Impact factor: 3.199

5.  Managing bile acid diarrhoea.

Authors:  Julian R F Walters; Sanjeev S Pattni
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

6.  Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-04-30       Impact factor: 4.052

7.  Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit.

Authors:  Michael Camilleri; Eric W Klee; Andrea Shin; Paula Carlson; Ying Li; Madhusudan Grover; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

8.  Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Alessandro Magni; Marina Del Puppo; Gian Nicola Gallus; Ingemar Björkhem; Antonio Federico; Maria Teresa Dotti
Journal:  J Inherit Metab Dis       Date:  2015-07-08       Impact factor: 4.982

9.  Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.

Authors:  Suwebatu T Odunsi-Shiyanbade; Michael Camilleri; Sanna McKinzie; Duane Burton; Paula Carlson; Irene A Busciglio; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-30       Impact factor: 11.382

10.  Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument.

Authors:  Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-20       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.